GL1X · GenesisL1 explorer

Research workbench

Crystal structure of drug resistant src kinase domain with irreversible inhibitor

Analyse Crystal structure of drug resistant src kinase domain with irreversible… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2QQ7
Type
protein
Length
495 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Proto-oncogene tyrosine-protein kinase src
EC
2.7.10.2
UniProt
P00523
Ligands
SR2
Pockets
4 · best druggability 0.74

Structure

x-ray diffraction · 2 distinct chains · 39% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein25139% helix, 16% strandP00523
BProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein24438% helix, 17% strandP00523

Ligands and binding sites

  • SR2 · (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110440.740.7796SR2
2970.600.8721empty
31780.540.7923SR2
4500.350.7914empty

Interfaces

1 interface between chains.

  • A–B · 344 Ų buried · 5 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 2QQ7 · Crystal structure of drug resistant SRC kinase domain with irreversible inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.